SG&A Reduction and Improved Capital Efficiency
First written in FY2019. 8 of 17 entries say "Advanced", first in FY2020-Q1. Latest entry: 2026-08-07.
- FY2026WorsenedAnnual report
「We recognized ¥26,872 million in other expenses for measures implemented to transform our global organizational structure and optimize headcount.」
Against the theme of SG&A reduction and improved capital efficiency, the Company recorded ¥26.872 billion in costs for organizational changes and headcount optimization measures. - FY2026-H1New fixed-cost reduction planAnnual report
「At a Board of Directors meeting held on 7 November 2025, the Company resolved to implement measures to transform its organizational structure globally and optimize its headcount. The measures are scheduled to be implemented over the period from the fiscal year ending March 2026 through the fiscal year ending March 2027, and are expected to reduce fixed costs by approximately ¥24.0 billion annually.」
The Company newly resolved a plan to transform its global organization and optimize its headcount from the fiscal year ending March 2026 through the fiscal year ending March 2027, reducing fixed costs by approximately ¥24.0 billion annually. - FY2025WorsenedAnnual report
「Selling, general and administrative expenses increased by ¥28.896 billion year on year to ¥495.654 billion.」
Against the theme of SG&A reduction and improved capital efficiency, selling, general and administrative expenses increased 6.2% year on year. - FY2025-H1WorsenedAnnual report
「Selling, general and administrative expenses increased by ¥19.426 billion year on year to ¥237.907 billion. The main factors were higher research and development expenses related to next-generation endoscopy systems and higher costs associated with Elevate, a comprehensive quality transformation program.」
Against the theme of SG&A reduction and improved capital efficiency, first-half selling, general and administrative expenses increased by ¥19.426 billion year on year. Higher R&D expenses and Elevate-related costs were cited as the factors. - FY2024WorsenedAnnual report
「Selling, general and administrative expenses increased by ¥52.684 billion year on year to ¥473.231 billion. The main factors were costs related to sustainable growth, including Elevate, a comprehensive quality transformation program, and the development and strengthening of the operational platform aimed at improving productivity.」
SG&A increased 12.5% year on year and deteriorated relative to the cost-reduction target due to higher costs for quality transformation and strengthening the operational platform. - FY2024-Q3WorsenedAnnual report
「Selling, general and administrative expenses increased by ¥34.822 billion year on year to ¥340.907 billion. The main factors were higher costs related to various projects aimed at improving efficiency and higher personnel expenses associated with future growth, quality assurance and regulatory compliance, and strengthening the operational platform.」
Against the theme of SG&A reduction and improved capital efficiency, selling, general and administrative expenses increased 11.4% year on year. The filing cites higher costs associated with growth investments, quality and regulatory compliance, and strengthening the operational platform. - FY2024-Q2WorsenedAnnual report
「The amount increased by ¥23,098 million year on year to ¥221,633 million. The main factors were higher personnel expenses associated with various project-related costs aimed at improving efficiency and strengthening the business operating platform, including future growth, quality assurance, and regulatory compliance.」
Against the theme of SG&A reduction and improved capital efficiency, selling, general and administrative expenses increased 11.6% year on year. The filing cites higher costs associated with growth investments, quality and regulatory compliance, and strengthening the business platform. - FY2022AdvancedAnnual report
「Although the Company pursued greater SG&A efficiency, the operating margin for the current consolidated fiscal year was 17.7%, an improvement of 6.5 percentage points year on year, due to the spread of COVID-19.」
Against the target of an operating margin exceeding 20% for the fiscal year ending March 2023, the margin improved to 17.7% in FY2022. - FY2021-Q1AdvancedAnnual report
「The group's consolidated revenue for the first quarter decreased 21.7% year on year to ¥142.403 billion. Revenue declined in all businesses due to restrictions on promotional activities and other factors resulting from the COVID-19 pandemic. The operating result was ¥1.19 billion, down 91.9% year on year, as the decline in revenue across all businesses outweighed the decrease in selling, general and administrative expenses.」
Although the Company reduced selling, general and administrative expenses, the impact of lower revenue across all businesses was greater, resulting in a substantial decline in operating income. - FY2020AdvancedAnnual report
「Despite the impact of COVID-19, the operating margin for the current consolidated fiscal year was 10.5%, an improvement of 6.9 percentage points year on year, as a result of more efficient SG&A management.」
More efficient SG&A management improved the operating margin to 10.5%, an improvement of 6.9 percentage points year on year. - FY2020-Q2AdvancedAnnual report
「Operating income improved substantially as the endoscopy, therapeutic solutions, and scientific solutions businesses reported higher earnings, expenses were managed more efficiently, and the ¥38,320 million in other expenses recorded in the previous year as one-time costs, including settlement payments related to a securities lawsuit, costs associated with reorganizing production sites for the imaging business, damages related to a court judgment involving a Chinese production subsidiary, and costs associated with entering into a deferred prosecution agreement with the U.S. Department of Justice, was no longer incurred. Operating income was ¥50,937 million, compared with ¥2,985 million in the same period of the previous year.」
As a result of more efficient cost management and the absence of one-time costs incurred in the same period of the previous year, operating income improved from ¥2,985 million to ¥50,937 million. - FY2020-Q1AdvancedAnnual report
「Operating income improved substantially as the endoscopy and scientific solutions businesses reported higher earnings, SG&A was controlled, and the ¥27,865 million in other expenses recorded in the previous year as one-time costs, including settlement payments related to a damages lawsuit, costs associated with reorganizing production sites for the imaging business, and damages related to a court judgment involving a Chinese production subsidiary, was no longer incurred. Operating income was ¥14,736 million, compared with an operating loss of ¥11,639 million in the same period of the previous year.」
The Company controlled SG&A, and together with the absence of the ¥27,865 million in one-time costs recorded in the same period of the previous year, this contributed to the improvement in operating income. - FY2019First statedAnnual report
「④ Initiatives to reduce costs and improve capital efficiency ・Improved operating margin: reduce SG&A in the fiscal year ending March 2020 to the level of the fiscal year ending March 2018 ・Improved capital efficiency: review capital expenditures and working capital for each business and steadily increase free cash flow for strategic business investment and shareholder returns」
The Company set a target of reducing SG&A to the fiscal year ending March 2018 level by the fiscal year ending March 2020 and improving capital efficiency by reviewing capital expenditures and working capital and increasing free cash flow.